To develop OliX’s OLX75016 candidate primarily targeting metabolic-associated steatohepatitis (MASH).
Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback